Mobile Header

Achieve Better Outcomes

Blood volume measurement ends the debate by taking the guesswork out of determining a patient’s blood
volume status — significantly improving multiple measures of patient outcomes by enabling volume guided management.

Significantly Reduce Heart Failure Mortality & Readmissions

Propensity matched-control trial in community hospital   |   n = 245, Mixed HFpEF/HFrEF

(P<0.001)

(P<0.001)

(P<0.001)

Blood Volume Measurements Improved ICU Survival

Prospective randomized control trial in surgical ICU   |   n = 100, 70% Septic Shock/Sepsis/40% ARDS

(P=0.03)

(P=0.14)

36 Hour Earlier
Treatment Decision

44% Change in Treatment
Strategy Versus Standard Care

Excellent Value in Healthcare

Blood Volume-Guided Treatment Extremely Cost-Effective

Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF

Well above the 0.227 previously reported

Far below the ICER threshold of $50,000

Approved for Reimbursement

Token Sale

Finding a Solution for the Most
Common & Costly Conditions

Blood volume derangements are common in a broad range of
medical and surgical conditions including heart failure, critical care,
sepsis, syncope, surgical blood loss, and ARDS.

Heart Failure

Critical Care

Sepsis

Syncope

Surgical Blood Loss

ARDS

Token Sale

Where Blood Volume Measurement Makes an Impact

Watch Our Story

In the Spotlight

Watch Daxor CEO, Michael Feldschuh, Discuss How BVA-100 Technology is Joining to Fight COVID-19

Published Research from Leading Institutions Has Established
the Value of Blood Volume Measurement Using the BVA-100 Test

Columbia University, Duke Health, Geisinger, Mayo Clinic, New York University,
Yale University, Vanderbilt University, Virginia Commonwealth University

Published Research from Leading Institutions
Has Established the Value of the BVA-100 Test

Columbia University, Duke Health, Geisinger, Mayo Clinic, New York University, Yale University, Vanderbilt University, Virginia Commonwealth University

Token Sale

Understanding More for
Providers, Payers, Patients

Providers

Enables better clinical decisions to
improve quality of care

Payers

Reduces mortality and readmissions
and lowers the cost of care

Patients

Provides your doctor with the information
needed to optimize treatment

Providers

Enables better clinical decisions to improve quality of care

Payers

Reduces mortality and readmissions and lowers the cost of care

Patients

Provides your doctor with the information needed to optimize treatment

Token Sale

News & Events

Information

Product Brochure

Special Report

Partner With the Dedicated Leader in BVA

As the pioneer in blood volume analysis, Daxor provides education and the resources needed to ensure easy onboarding along with continuing support to drive maximum value from your BVA system throughout your facility. With a long-standing commitment to improving care and numerous studies validating our technology, Daxor is completely focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. Our vision is optimal blood volume for all.

Volume is Vital. End the Debate With Daxor.

Call us at 865-425-0555.

 

Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions.

Daxor Corporation – 107 Meco Lane, Oak Ridge, TN 37830
Phone: 865-425-0555 | Fax: 516-828-4772
info@daxor.com | daxor.com

ISO 13485 Certified

Made in the USA.

COPYRIGHT 2021 © DAXOR CORPORATION – ALL RIGHTS RESERVED.